| CAR-T cells with phytohemagglutinin (PHA) provide anti-cancer capacity with better proliferation, rejuvenated effector memory, and reduced exhausted t cell frequencies G Gulden, B Sert, T Teymur, Y Ay, NN Tiryaki, AK Mishra, E Ovali, ... Vaccines 11 (2), 313, 2023 | 4 | 2023 |
| Exon7 Targeted CRISPR-Prime Editing Approaches for SMN2 Gene Editing in Spinal Muscular Atrophy (SMA) Disease Can Increase In Vitro SMN Expression SP Odabas, E Bal, G Yelgen, AS Metin, E Karakaya, G Gulden, B Sert, ... bioRxiv, 2022.03. 21.484406, 2022 | 2 | 2022 |
| Development of DNA ink & DNA barcoding technology on practical tracking & authenticity detection of pharmaceutical ingredients B Budaklar, B Sert, G Gülden, C Taştan Gene Edit 3 (3), 19-29, 2022 | 1 | 2022 |
| MESSAGE Mission: Understanding the immune system and cancer connection in microgravity B Sert, G Gülden, F Erkek, Ö Demir, E Çam, B Tekirdağlı, C Taştan Free Radical Biology and Medicine 218, 55-56, 2024 | | 2024 |
| Enhancing CAR-T cells: unleashing lasting impact potential with phytohemagglutinin activation in in vivo leukemia model B Sert, G Gulden, T Teymur, Y Ay, RD Turan, OM Unaldi, E Guzenge, ... Cancer Gene Therapy 31 (3), 387-396, 2024 | | 2024 |
| Making Antibiotic-Resistant E. coli Non-Resistant with CRISPR/Cas9 Gene Editing I Cavrar, B Sert, G Gülden, C Taştan Gene Editing 1 (4), 25-30, 2023 | | 2023 |
| The Effect Of Beta-Lactam-Containing Drugs On The Development Of Drug Allergy D Bakaçhan, B Sert, MK Zelka, G Gulden, C Tastan Gene Editing 1 (4), 14-24, 2023 | | 2023 |
| Sensitization of The Antibiotic Resistant M. smegmatis Bacteria Using CRISPR/FnCpf1 Gene Editing H Araz, G Gulden, B Sert, C Taştan Gene Editing 1 (4), 1-13, 2023 | | 2023 |
| Current Challenges and Potential Strategies for Designing a New Generation of Chimeric Antigen Receptor-T cells with High Anti-tumor Activity in Solid Tumors D Sahan Khankishiyev, G Gulden, B Sert, C Tastan Current Tissue Microenvironment Reports 4 (1), 1-16, 2023 | | 2023 |
| Phytohemagglutinin-Activated CAR-T Cells: Prolonged Persistence and Enhanced Anti-Tumor Response in CD19-Specific Acute Lymphoblastic Leukemia B Sert, G Gulden, T Teymur, Y Ay, RD Turan, OM Unaldi, E Guzenge, ... bioRxiv, 2023.07. 15.547808, 2023 | | 2023 |
| The CRISPR-Cas12 SHERLOCK System Can Identify HIV CC İnci, G Gülden, B Sert, C Taştan Gene Editing 3 (3), 14-18, 2022 | | 2022 |
| Expression of Axolotl P53 Gene May Increase Cancer Resistance HA Babar, Ö Kılıç, G Gülden, B Sert, C Taştan Gene Editing 3 (3), 30-34, 2022 | | 2022 |
| In-vitro Investigation of Proliferation, Differentiation and Survival Capacity of Mesenchymal Stem Cells, Cancer and Lymphocytes in an Acoustic Levitation Device Providing … C Tastan, B Tekirdagli, E Cam, O Demir, B Sert, G Gulden 44th COSPAR Scientific Assembly. Held 16-24 July 44, 2855, 2022 | | 2022 |
| Exon7 Targeted CRISPR-Prime Editing Approaches for SMN2 Gene Editing in Spinal Muscular Atrophy Yazarlar IC C. Tastan G. Yelgen, E. Bal, S.P. Odabas, F.N. Erkek, G. Gulden, B. Sert ... 11th European Conference on Rare Diseases & Orphan Products - Poster …, 2022 | | 2022 |
| Autonomous Remotely Controlled Closed System Transgenic Cell Technologies Robot: CRISPR. BOT (preprint) F Erkek, G Gulden, B Sert, MC Yilmaz, SP Odabas, E Bal, G Yelgen, ... | | 2022 |
